139 related articles for article (PubMed ID: 21641013)
1. Activation of the phosphatidylinositol 3'-kinase/AKT pathway in neuroblastoma and its regulation by thioredoxin 1.
Sartelet H; Rougemont AL; Fabre M; Castaing M; Duval M; Fetni R; Michiels S; Beaunoyer M; Vassal G
Hum Pathol; 2011 Nov; 42(11):1727-39. PubMed ID: 21641013
[TBL] [Abstract][Full Text] [Related]
2. Activation of Akt predicts poor outcome in neuroblastoma.
Opel D; Poremba C; Simon T; Debatin KM; Fulda S
Cancer Res; 2007 Jan; 67(2):735-45. PubMed ID: 17234785
[TBL] [Abstract][Full Text] [Related]
3. Growth inhibition of human malignant glioma cells induced by the PI3-K-specific inhibitor.
Shingu T; Yamada K; Hara N; Moritake K; Osago H; Terashima M; Uemura T; Yamasaki T; Tsuchiya M
J Neurosurg; 2003 Jan; 98(1):154-61. PubMed ID: 12546364
[TBL] [Abstract][Full Text] [Related]
4. Phosphatidylinositol 3-kinase regulation of gastrin-releasing peptide-induced cell cycle progression in neuroblastoma cells.
Ishola TA; Kang J; Qiao J; Evers BM; Chung DH
Biochim Biophys Acta; 2007 Jun; 1770(6):927-32. PubMed ID: 17379415
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the phosphatidylinositol-3 kinase/Akt promotes G1 cell cycle arrest and apoptosis in Hodgkin lymphoma.
Georgakis GV; Li Y; Rassidakis GZ; Medeiros LJ; Mills GB; Younes A
Br J Haematol; 2006 Feb; 132(4):503-11. PubMed ID: 16412023
[TBL] [Abstract][Full Text] [Related]
6. Receptor tyrosine kinase and phosphoinositide-3 kinase signaling in malignant mesothelioma.
Rascoe PA; Cao X; Daniel JC; Miller SD; Smythe WR
J Thorac Cardiovasc Surg; 2005 Aug; 130(2):393-400. PubMed ID: 16077404
[TBL] [Abstract][Full Text] [Related]
7. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
Festuccia C; Muzi P; Millimaggi D; Biordi L; Gravina GL; Speca S; Angelucci A; Dolo V; Vicentini C; Bologna M
Endocr Relat Cancer; 2005 Dec; 12(4):983-98. PubMed ID: 16322337
[TBL] [Abstract][Full Text] [Related]
8. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways.
Han S; Khuri FR; Roman J
Cancer Res; 2006 Jan; 66(1):315-23. PubMed ID: 16397245
[TBL] [Abstract][Full Text] [Related]
9. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics.
Zhong H; Chiles K; Feldser D; Laughner E; Hanrahan C; Georgescu MM; Simons JW; Semenza GL
Cancer Res; 2000 Mar; 60(6):1541-5. PubMed ID: 10749120
[TBL] [Abstract][Full Text] [Related]
10. Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) reduces vascular endothelial growth factor expression in allergen-induced airway inflammation.
Lee KS; Kim SR; Park SJ; Lee HK; Park HS; Min KH; Jin SM; Lee YC
Mol Pharmacol; 2006 Jun; 69(6):1829-39. PubMed ID: 16527906
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells.
Ikezoe T; Nishioka C; Bandobashi K; Yang Y; Kuwayama Y; Adachi Y; Takeuchi T; Koeffler HP; Taguchi H
Leuk Res; 2007 May; 31(5):673-82. PubMed ID: 17007924
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
[TBL] [Abstract][Full Text] [Related]
13. Effects of inhibitors of vascular endothelial growth factor receptor 2 and downstream pathways of receptor tyrosine kinases involving phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin or mitogen-activated protein kinase in canine hemangiosarcoma cell lines.
Adachi M; Hoshino Y; Izumi Y; Sakai H; Takagi S
Can J Vet Res; 2016 Jul; 80(3):209-16. PubMed ID: 27408334
[TBL] [Abstract][Full Text] [Related]
14. Aldo-keto reductase 1C3 (AKR1C3) is associated with the doxorubicin resistance in human breast cancer via PTEN loss.
Zhong T; Xu F; Xu J; Liu L; Chen Y
Biomed Pharmacother; 2015 Feb; 69():317-25. PubMed ID: 25661377
[TBL] [Abstract][Full Text] [Related]
15. Topotecan blocks hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression induced by insulin-like growth factor-I in neuroblastoma cells.
Beppu K; Nakamura K; Linehan WM; Rapisarda A; Thiele CJ
Cancer Res; 2005 Jun; 65(11):4775-81. PubMed ID: 15930297
[TBL] [Abstract][Full Text] [Related]
16. Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors.
Batista A; Barata JT; Raderschall E; Sallan SE; Carlesso N; Nadler LM; Cardoso AA
Exp Hematol; 2011 Apr; 39(4):457-472.e3. PubMed ID: 21277936
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of Aiolos in Nalm-6 acute lymphoblastic leukaemia cells reduces apoptosis by suppressing phosphatase and tensin homologue deleted on chromosome 10 and activating the phosphatidylinositol-3-kinase/Akt signalling pathway.
Wang R; Guo G; Li H; Li X; Yu Y; Li D
Mol Med Rep; 2015 May; 11(5):3457-64. PubMed ID: 25608224
[TBL] [Abstract][Full Text] [Related]
18. Differential response of neuroblastoma cells to TRAIL is independent of PI3K/AKT.
Efron PA; Chen MK; Iyengar M; Dai W; Nagaram A; Beierle EA
J Pediatr Surg; 2006 Jun; 41(6):1072-80. PubMed ID: 16769337
[TBL] [Abstract][Full Text] [Related]
19. Reconstitution of the mammalian PI3K/PTEN/Akt pathway in yeast.
Rodríguez-Escudero I; Roelants FM; Thorner J; Nombela C; Molina M; Cid VJ
Biochem J; 2005 Sep; 390(Pt 2):613-23. PubMed ID: 15913452
[TBL] [Abstract][Full Text] [Related]
20. Effects of epidermal growth factor receptor and phosphatase and tensin homologue gene expression on the inhibition of U87MG glioblastoma cell proliferation induced by protein kinase inhibitors.
Xing WJ; Zou Y; Han QL; Dong YC; Deng ZL; Lv XH; Jiang T; Ren H
Clin Exp Pharmacol Physiol; 2013 Jan; 40(1):13-21. PubMed ID: 23110505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
